<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62037">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858636</url>
  </required_header>
  <id_info>
    <org_study_id>CL06818</org_study_id>
    <nct_id>NCT01858636</nct_id>
  </id_info>
  <brief_title>Post-Market Study of the St. Jude Medical Angio-Seal™ VIP Vascular Closure Device</brief_title>
  <acronym>SEAL PM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the clinical outcomes of Angio-Seal VIP with SJM collagen through the
      collection of device/procedure-related major vascular complications and time to hemostasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The proportion of subjects experiencing a device or procedure related major vascular complication</measure>
    <time_frame>30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major vascular complications include:
Access Site Complications:
Hematoma &gt;10 cm in size
Major bleeding requiring transfusion of ≥2 units of blood
Pain requiring extended or new hospitalization, or percutaneous or surgical intervention
Infection requiring extended or new hospitalization or treatment with IV antibiotics
A/V Fistula requiring medical intervention (percutaneous or surgical)
Pseudoaneurysm requiring medical intervention (percutaneous or surgical)
Lower Limb Ischemia requiring surgical or medical intervention or resulting in permanent injury/impairment
Retroperitoneal hemorrhage requiring intervention (percutaneous or surgical)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects that achieve hemostasis within 5 minutes of device deployment.</measure>
    <time_frame>within 5 minutes of device deployment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">235</enrollment>
  <condition>Vascular Closure</condition>
  <arm_group>
    <arm_group_label>Angio-Seal VIP Vascular Closure</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angio-Seal VIP 6F and 8F devices</intervention_name>
    <description>These devices are used for the vascular closure procedure</description>
    <arm_group_label>Angio-Seal VIP Vascular Closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that will be included in the study will be indicated for the procedure according
        to the Instructions for Use. Physicians should carefully select patients based on the IFU
        including a consideration of all warnings and precautions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient requires closure of femoral artery puncture resulting from arterial access
             procedure.

          -  Patient is ≥18 years of age.

          -  Patient is willing to provide written informed consent prior to study device use.

          -  Patient is willing and able to adhere to data collection and follow-up requirements.

        Exclusion Criteria:

          -  Patient is participating in another clinical trial which has the potential to impact
             hemostasis.

          -  Patient has an active groin infection or systemic infection.

          -  Patient has undergone a vascular access procedure within the past 90 days.

          -  Patient has been previously enrolled in the study.  (For patients undergoing multiple
             interventions within a timeframe of 90 days, only the initial procedure may
             constitute a study enrollment.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Diagnostiche und Interventionelle Radiologie</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GMBH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
